Andrew Doan, MD

Attending Physician; Hematology, Oncology and Blood and Marrow Transplantation
Assistant Professor of Pediatrics, Keck School Medicine of USC

Dr. Doan joined the Blood and Marrow Transplant team as a hospitalist in 2016. During his fellowship, he developed his clinical and research interest in cancer genomics and cancer risk predisposition,as well as, solid tumors. In collaboration with University of Chicago, he developed a Genomics Consortium aimed at developing a pipeline that incorporates clinical information with next generation sequencing to describe the incidence and spectrum of germline mutations in genes associated with familial cancer syndromes in pediatric cancer.

Clinical Interests

Blood and Marrow Transplantation

Education

Medical School

Rutgers Robert Wood Johnson Medical School

Internship

General Pediatrics: Rutgers Robert Wood Johnson Medical School

Residency

General Pediatrics: Rutgers Robert Wood Johnson Medical School

Fellowship

Northwell Health Steven and Alexandra Cohen Children's Medical Center

Accomplishments

Certifications

General Pediatrics: American Board of Pediatrics

Professional Memberships

American Society of Pediatric Hematology Oncology
Children’s Oncology Group

Publications

Refereed Reviews, Chapters, and Editorials:

Navin Pinto, MD, Samuel L Volchenboum, MD, PhD, Andrew D Skol, PhD, Lindsay Rhodes, MS, CGC, Andrew Doan, MD, Carolyn Fein Levy, MD, Jeffrey M Lipton, MD, PhD, John M Cunningham, MD, Kenan Onel, MD, PhD. A practical primer for establishing a translational genomics infrastructure in pediatric cancer: The University of Chicago GREAT KIDS experience. Personalized Medicine, 2015

Abstracts and Presentations:

Mark Bittman, MD, Andrew Doan, MD, Carolyn Fein Levy,MD. Unusual Cancers of Childhood: Rare Abdominopelvic and Thoracic Tumors. Educational Exhibit.  Presented at: The Society for Pediatric Radiology, Annual Meeting, Bellevue, WA, USA, April 2015

Katte Carreon, MD, Andrew Doan, MD, Carolyn Fein-Levy, MD, Arlene Redner, MD, Morris Edelman, MD. Osteosarcoma: Is Post-chemotherapy Necrosis an Overvalued Prognostic Marker? Presented at: United States and Canadian Academy of Pathology Annual Meeting, Boston, MA, USA, March 2015

Andrew Doan, MD, Richard D. Glick, MD, Nelson G. Rosen, MD, Morris Edelman, MD, Lee Collins, MD, A. Lindsay Frazier, MD, Carolyn Fein Levy, MD.  The Use of Modified Head Start II Chemotherapy in Germ Cell Tumors with Somatic Malignant Transformation: A Report of Two Cases.  Presented at: American Society of Pediatric Hematology/Oncology Annual Meeting, Minneapolis, MN, USA, May 2016

Andrew Doan, MD, Derek Hanson, MD, Mark E. Bittman, MD, Alex K. Williamson, MD, Morris Edelman, MD, Gregory J. Riely, MD, Carolyn Fein Levy, MD.  The Use of Sunitinib as Maintenance Chemotherapy in Pediatric Patient with a Poorly Differentiated Thymic Carcinoma.  Presented at: American Society of Pediatric Hematology/Oncology Annual Meeting, Minneapolis, MN, USA, May 2016

Research

  • Cancer Genomic and Solid tumors